Skip to main content
All lobbying filings

TODD STRATEGY GROUP

Lobbying for ALKERMES, INC. · ​Pharmaceutical manufacturing and biopharmaceutical company.

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 5
  • ERIC BERGREN
    Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
  • KATHERINE FLEMING COTTON
    Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
  • TED LEHMAN
    Previously held: Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant
  • TAYLOR SEXTON
    Previously held: Advisor to the Assistant Secretary for Preparedness & Response, HHS; Advisor to the Assistant Secretary of Legislation, HHS; Health Care Policy Fellow, Representative Michael Burgess
  • KIMBERLY LINTHICUM
    Previously held: Legislative Director, Representative Bob Franks; Legislative Correspondent, Representative Charles Taylor; Legislative Correspondent, Representative Bill Martini

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 1
Health Issues

Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem